DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection

Human Gene Therapy

Volumn 17, Issue 1, 2006, Pages 81-92

  Facciabene, Andrea ^a,b   Aurisicchio, Luigi ^a   Elia, Leonardo ^a   Palombo, Fabio ^a   Mennuni, Carmela ^a   Ciliberto, Gennaro ^a   La Monica, Nicola ^a  

^a IRBM   (Italy)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GENE PRODUCT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; POLYPEPTIDE; TETANUS TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA VECTOR; GENE SEQUENCE; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PLASMID; REGULATORY T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR GROWTH; VIRAL GENE THERAPY; WILD TYPE;

ADENOVIRIDAE; ANIMALS; BLOOD PROTEINS; CARCINOEMBRYONIC ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPITOPES; GENETIC VECTORS; HELA CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; PLASMIDS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TETANUS TOXOID; TRANSFECTION;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 30744442807     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.81     Document Type: Article

References (34)

1. BABIUK, S., BACA-ESTRADA, M.E., FOLDVARI, M., STORMS, M., RABUSSAY, D., WIDERA, G., and BABIUK, L.A. (2002). Electroporation improves efficacy of DNA vaccines in large animals. Vaccine 20, 3399-3408.
2. BRONTE, V. (2001). Genetic vaccination for the active immunotherapy of cancer. Curr. Gene Ther. 1, 53-100.
3. BRUNA-ROMERO, O., GONZALEZ-ASEGUINOLAZA, G., HAFALLA, J.C., TSUJI, M., and NUSSENZWEIG, R.S. (2001). Complete, long lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. U.S.A. 98, 11491-11496.
4. CASIMIRO, D.R., TANG, A., CHEN, L., FU, T.M., EVANS, R.K., DAVIES, M.E., FREED, D.C., HURNI, W., ASTE-AMEZAGA, J.M., GUAN, L., LONG, R., HUANG, L., HARRIS, V., NAWROCKI, D.K., MACH, H., TROUTMAN, R.D., ISOPI, L.A., MURTHY, K.K., RICE, K., WILSON, K.A., VOLKIN, D.B., EMINI, E.A., and SHIVER, J.W. (2003). Vaccine induced immunity in baboons using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type I gag gene. J. Virol. 77, 7663-7668.
5. CHEN, C.H., WANG, T.L., HUNG, C.F., YANG, Y., YOUNG, R.A., PARDOLL, D.M., and WU, T.C. (2000). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60, 1035-1042.
6. CLARKE, P., MANN, J., SIMPSON, J.F., RICKARD-DICKSON, K., and PRIMUS, F.J. (1998). Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 58, 1469-1477.
7. + cytotoxic T lymphocyte population. Int. Immunol. 14, 31-37.
8. FACCIABENE, A., AURISICCHIO, L., and LA MONICA, N. (2004). Baculovirus vectors elicit antigen specific immune responses in mice. J. Virol. 78, 8663-8672.
9. GONZALO, R.M., DEL REAL, G., RODRIGUEZ, J.R., RODRIGUEZ, D., HELJASVAARA, R., LUCAS, P., LARRAGA, V., and ESTEBAN, M. (2002). A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 20, 1226-1231.
10. GURUNATHAN, S., WU, C.Y., FREIDAG, B.L., and SEDER, R.A. (2000). DNA vaccines: A key for inducing long-term cellular immunity. Curr. Opin. Immunol. 12, 442-447.
11. HUANG, E.H., and KAUFMAN, H.L. (2002). CEA-based vaccines. Expert Rev. Vaccines 1, 49-63.
12. + T lymphocytes. Nature 421, 852-856.
13. LIU, D.W., TSAO, Y.P., KUNG, J.T., DING, Y.A., SYTWU, H.K., XIAO, X., and CHEN, S.L. (2000). Recombinant adeno-associated virus expressing human papilloma virus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. 74, 2888-2894.
14. LUND, L.H., ANDERSSON, K., ZUBER, B., KARLSSON, A., ENGSTROM, G., HINKULA, J., WAHREN, B., and WINBERG, G. (2003). Signal sequence deletion, and fusion to tetanus toxoid epitope augment antitumor responses to a human carcinoembryonic antigen (CEA) plasmid DNA in a murine test system. Cancer Gene Ther. 10, 365-376.
15. MENNUNI, C., CALVARUSO, F., FACCIABENE, A., AURISICCHIO, L., STORTO, M., SCARSELLI, E., CILIBERTO, G., and LA MONICA, N. (2005). Efficient induction of T cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int. J. Cancer 117, 444-455.
16. PIERONI, L., MAIONE, D., and LA MONICA, N. (2001). In vivo gene transfer in mouse skeletal muscle mediated by baculovirus vectors. Hum. Gene Ther. 12, 871-881.
17. RENARD, V., SONDERBYE, L., EBBEHOJ, K., RASMUSSEN, P.B., GREGORIUS, K., GOTTSCHALK, T., MOURITSEN, S., GAUTAM, A., and LEACH, D.R. (2003). HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J. Immunol. 171, 1588-1595.
18. RICE, J., ELLIOTT, T., BUCHAN, S., and STEVENSON, F.K. (2001). DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: Implications for cancer vaccines. J. Immunol. 167, 1558-1565.
19. RICE, I., BUCHAN, S., and STEVENSON, F.K. (2002). Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J. Immunol. 169, 3908-3913.
20. RIZZUTO, G., CAPPELLETTI, M., MAIONE, D., SAVING, R., LAZZARO, D., COSTA, P., MATHIESEN, I., CORTESE, R., CILIBERTO, G., LAUFER, R., LA MONICA, N., and FATTORI, E. (1999). Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc. Natl. Acad. Sci. U.S.A. 96, 6417-6422.
21. + regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18-32.
22. + T-cell mediated immunity against B-cell malignancies. Nat. Biotechnol. 19, 760-764.
23. SCHEERLINCK, J.P., KARLIS, J., TJELLE, T.E., PRESIDENTE, P.J., MATHIESEN, I., and NEWTON, S.E. (2004). In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 22, 1820-1825.
24. SHIVELY, J.E., and BETTAY J.D. (1985). CEA-related antigen: Molecular and clinical significance. Crit. Rev. Oncol. Hematol. 2, 355-399.
25. SHIVER, J.W., FU, T.M., CHEN, L., CASIMIRO, D.R., DAVIES, M.E., EVANS, R.K., ZHANG, Z.Q., SIMON, A.J., TRIGONA, W.L., DUBEY, S.A., HUANG, L., HARRIS, V.A., LONG, R.S., LIANG, X., HANDT, L., SCHLEIF, W.A., ZHU, L., FREED, D.C., PERSAUD, N.V., GUAN, L., PUNT, K.S., TANG, A., CHEN, M., WILSON, K.A., COLLINS, K.B., HHDECKER, G.I., FERNANDEZ, V.R., PERRY, H.C., JOYCE, J.G., GRIMM, K.M., COOK, J.C., KELLER, P.M., KRESOCK, D.S., MACH, H., TROUTMAN, R.D., ISOPI, L.A., WILLIAMS, D.M., XU, Z., BOHANNON, K.E., VOLKIN, D.B., MONTEFIORI, D.C., MIURA, A., KRIVULKA, G.R., LIFTON, M.A., KURODA, M.I., SCHMITZ, I.E., LETVIN, N.L., CAULFIELD, M.J., BETT, A.J., YOUIL, R., KASLOW, D.C., and EMINI, E.A. (2002). Replication incompetent adenoviral vector elicits effective anti- immunodeficiency virus immunity. Nature 415, 331-335.
26. SOARES, M.M., MEHTA, V., and FINN, O.J. (2001). Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166, 6555-6563.
27. STEVENSON, F.K., RICE, I., OTTENSMEIER, C.H., THIRDBOROUGH, S.M., and ZHU, D. (2004). DNA fusion gene vaccines against cancer: From the laboratory to the clinic. Immunol. Rev. 199, 156-180.
28. + T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 62, 5041-5048.
29. THOMPSON, J.A., GRUNERT, F., and ZIMMERMANN, W. (1991). Carcinoembryonic antigen gene family: Molecular biology and clinical perspective. J. Clin. Lab. Anal. 5, 344-366.
30. ULLENHAG, G.J., FAGERBERG, J., STRIGARD, K., FRODIN, J.E., and MELLSTEDT, H. (2004). Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA. Cancer Immunol. Immunother. 53, 331-337.
31. WIDERA, G., AUSTIN, M., RABUSSAY, D., GOLDBECK, C., BARNETT, S.W., CHEN, M., LEUNG, L., OTTEN, G.R., THUDIUM, K., SELBY, M.J., and ULMER, I.E. (2000). Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164, 4635-4640.
32. WIERZBICKI, A., KISZKA, I., KANEKO, H., KMIECIAK, D., WASIK, T.I., GZYL, I., KANEKO, Y., and KOZBOR, D. (2002). Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine 20, 1295-1307.
33. YOU, Z., HUANG, X.F., HESTER, I., ROLLINS, L., ROONEY, C., and CHEN, S.Y. (2000). Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor mediated internalization pathway. J. Immunol. 165, 4581-4592.
34. ZUCCHELLI, S., CAPONE, S., FATTORI, E., FOLGORI, A., DI MARCO, A., CASIMIRO, D., SIMON, A.I., LAUFER, R., LA MONICA, N., CORTESE, R., and NICOSIA, A. (2000). Enhancing B- and T-cell immune response to hepatitis C virus E2 DNA vaccine intramuscular electrical gene transfer. J. Virol. 74, 11598-11607.